723-87-5

Basic information

• Product Name: 11-Hydroxy-5H-dibenzo[b,e]azepin-6(11H)-one
• Synonyms: 11-Hydroxy-5H-dibenzo[b,e]azepin-6(11H)-one;11-hydroxy-5,11-dihydro-dibenzo[b,e]azepin-6-one
• CAS NO: 723-87-5
• Molecular Formula: C14H11NO2
• Molecular Weight: 225.24264
• Mol File: 723-87-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 331.662°C at 760 mmHg
• Flash Point: 154.384°C
• Appearance: /
• Density: 1.3g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.653
• CAS DataBase Reference: 11-Hydroxy-5H-dibenzo[b,e]azepin-6(11H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 11-Hydroxy-5H-dibenzo[b,e]azepin-6(11H)-one(723-87-5)
• EPA Substance Registry System: 11-Hydroxy-5H-dibenzo[b,e]azepin-6(11H)-one(723-87-5)

Safety Data

• Hazardous Substances Data: 723-87-5(Hazardous Substances Data)

Usage

General Description

11-Hydroxy-5H-dibenzo[b,e]azepin-6(11H)-one, also known as mianserin, is a psychoactive chemical compound that belongs to the tetracyclic antidepressant class of medications. It acts as a noradrenergic and specific serotonergic antidepressant (NaSSA) and is used to treat various conditions such as depression, anxiety, and insomnia. The compound works by increasing the levels of serotonin and norepinephrine in the brain, which helps to improve mood and alleviate symptoms of depression and anxiety. It is commonly available in tablet form for oral administration and has been found to be effective in the treatment of major depressive disorder and other mood disorders. However, it may also have potential side effects and interactions with other medications, so it should be used with caution and under the supervision of a healthcare professional.

InChI:InChI=1/C14H11NO2/c16-13-9-5-1-2-6-10(9)14(17)15-12-8-4-3-7-11(12)13/h1-8,13,16H,(H,15,17)

Upstream product

• 1143-50-6 5,6-dihydro-6,11-dioxomorphanthridine 
• 84-65-1 9,10-phenanthrenequinone 

Downstream Products

• 723-86-4 11-chloro-6-oxo-5,11-dihydro-6H-dibenzazepine 
• 1211-06-9 5,11-dihydro-6H-dibenz[b,e]azepin-6-one 
• 121112-96-7 11-Phenoxy-5,11-dihydro-dibenzo[b,e]azepin-6-one 
• 121112-85-4 11-Cyclohexylamino-5,11-dihydro-dibenzo[b,e]azepin-6-one 
• 121113-00-6 5-Benzyl-11-ethoxy-5,11-dihydro-dibenzo[b,e]azepin-6-one 
• 121112-91-2 N-phenyl-N'-isopropyl-N'-(5,6-dihydro-dibenzoazepin-6-one-11-yl)-urea 
• 121112-86-5 11-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-5,11-dihydro-dibenzo[b,e]azepin-6-one 
• 1334182-17-0 C₅₆H₆₇N₁₁O₁₀ 
• 1334182-18-1 C₅₇H₆₉N₁₁O₁₀ 
• 1334182-19-2 C₆₂H₇₁N₁₁O₁₀ 
• 1334182-20-5 C₆₃H₈₀N₁₂O₁₂ 
• 1334182-21-6 C₅₇H₇₀N₁₂O₉ 
• 1334182-22-7 C₅₇H₆₉N₁₁O₉ 
• 1334182-23-8 C₆₁H₆₉N₁₁O₉ 

Relevant articles and documents

Synthesis and SAR of selective small molecule neuropeptide y Y2 receptor antagonists

Highly potent and selective small molecule neuropeptide Y Y2 receptor antagonists are reported. The systematic SAR exploration of a hit molecule N-(4-ethoxyphenyl)-4-[hydroxy(diphenyl)methyl]piperidine-1-carbothioamide, identified from HTS, led to the discovery of highly potent NPY Y2 antagonists 16 (CYM 9484) and 54 (CYM 9552) with IC50 values of 19 nM and 12 nM respectively.

New Triazine Derivatives as Potent Modulators of Multidrug Resistance

A series of 70 triazine derivatives have been synthesized and tested for their capacity to modulate multidrug resistance (MDR) in DC-3F/AD and KB-A1 tumor cells in vitro, in comparison with verapamil (VRP), a calcium channel antagonist currently used in therapy as an antihypertensive drug, which also shows MDR modulating activity.Among the 12 selected compounds, 16 (S9788) showed high MDR reversing properties in vitro (300- and 6-fold VRP at 5μM in DC-3F/AD and KB-A1 cells, respectively) and induced a strong accumulation of adriamycin.The relationship between the increase of ADR accumulation and the fold reversal induced by these compounds and their lack of effects on the sensitive DC-3F cells suggest that they act mainly by inhibiting the P-glycoprotein (Pgp) catalyzed efflux of cytotoxic agents, as already described for a majority of MDR modulators.In vivo, in association with the antitumor drug vincristine (0.25 mg/kg), 16 (100 mg/kg) increased the T/C by 39percent in mice bearing the resistant tumor cell line P388/VCR.According to these interesting properties, 16 was selected for a clinical development because it is more bioavailable than 34, even though it was less active.